Donald A. Bergstrom - 15 Oct 2021 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Executive Vice President, Head of Research and Development
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
15 Oct 2021
Net transactions value
-$1,024,500
Form type
4
Filing time
19 Oct 2021, 20:56:17 UTC
Previous filing
27 Sep 2021
Next filing
27 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale $1,024,500 -30,000 -40% $34.15 45,619 15 Oct 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
F2 This transaction was executed in multiple trades at prices ranging from $33.309 to $36.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Executive Vice President, Head of Research and Development